CME Webcast Discusses New Therapies for Lung Cancer

OSUWexnerbloglogo2014 CME Webcast Discusses New Therapies for Lung Cancer. On this CME webcast, we’re going to update you on the medical management of lung cancer and focus on non-small cell lung cancer. Joining our moderator in the studio is medical oncologist at the James Cancer Hospital and Professor of Internal Medicine from the Ohio State University, Dr. David Carbone.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: Review some of the latest practice-changing findings in the management of lung cancer; and Understand the basic principles of workup and initial lung cancer management decisions.

You’ll also learn about the following:

  • Classifying non-small cell lung cancer
  • Common side effects of driver-targeted therapies
  • What the primary care physician needs to know about co-managing patients taking driver-targeted therapy

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

 

On-line CME Education Discusses Lymphoma

OSUWexnerbloglogo2014 On-line CME Education Discusses Lymphoma. Today, Hodgkin’s disease is curable in most patients with a 5-year survival rate of 86%. But this is only one type of lymphoma and as we’ll see today, hematologists have made enormous strides in the management of all types of lymphoma. Joining our moderator are two lymphoma experts from The Ohio State University and the James Cancer Hospital. Dr. Kami Maddocks is an Associate Professor of Internal Medicine from the Division of Hematology. And Dr. Beth Christian is also a hematologist and Associate Professor of Internal Medicine.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DEFINE the most common types of aggressive lymphomas, identify both urgent initial presentations and urgent complications of treatment, and outline standards of survivorship; and DESCRIBE the features of indolent non-Hodgkin lymphoma including the most common subtypes, follicular lymphoma, marginal zone lymphoma and Waldenström macroglobulinemia.

You’ll also learn about the following:

  • What causes lymphoma
  • The spectrum of lymphomas
  • Stem cell transplant in aggressive lymphomas
  • Whether there a role for “maintenance rituximab”
  • Chronic lymphocytic leukemia versus non-Hodgkin lymphoma
  • Lymphoma mimics
  • Deciding when to biopsy an enlarged lymph node

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

On-line CME Discussing Multiple Myeloma

OSUWexnerbloglogo2014 On-line CME Discussing Multiple Myeloma. In the past year, there have been 4 new drugs approved to treat multiple myeloma and these are changing the way that we manage patients with this disease. On this CME webcast, we’re going to talk about what multiple myeloma is, how you diagnosis it, and how it is treated. Joining our moderator in the studio is hematologist and Assistant Professor of Internal Medicine from the OSU Wexner Medical Center, Dr. Ashley Rosko. And also from the division of hematology, we have Associate Professor of Internal Medicine, Dr. Yvonne Efebera joining us.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: UNDERSTAND the difference between MGUS, smoldering Myeloma, Symptomatic multiple Myeloma; DESCRIBE the general clinical features of plasma cell myeloma including the diagnosis, and steps required for evaluation; UNDERSTAND Treatment strategy for Newly diagnosed Multiple Myeloma Patients Eligible for Transplant and Newly diagnosed Multiple Myeloma Patients not Eligible for Transplant.

You’ll also learn about the following:

  • Epidemiology of multiple myeloma
  • Prognosis of multiple myeloma
  • When to do a bone marrow biopsy?
  • Screening patients with kidney failure for multiple myeloma
  • Management of hypercalcemia and renal failure in multiple myeloma
  • Autologous versus allogenic stem cell transplant

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Discusses Acute and Chronic Myeloid Leukemia

OSUWexnerbloglogo2014CME Webcast Discusses Acute and Chronic Myeloid Leukemia. Joining our webcast to tell you all about the newest developments in chronic myelogenous leukemia is hematologist and Assistant Professor of Internal Medicine from the Ohio State University, Dr. Katherine Walsh. And then to tell you about acute myeloid leukemia is OSU hematologist and also Assistant Professor of Internal Medicine, Dr. Alice Mims.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: REVIEW the clinical presentation and diagnosis of CML; REVIEW the front line treatment options and milestones for response to treatment; DESCRIBE the clinical presentation and diagnosis of AML.

You’ll also learn about the following:

  • Presenting signs and symptoms of CML
  • Presenting signs and symptoms of AML
  • Stem cell transplant in CML
  • Initial evaluation and management of patients with suspected AML
  • Initial treatment of patients with AML
  • CML blast crisis
  • Leukemoid reaction versus CML
  • Which patients with AML require a lumbar puncture
  • Which patients with AML need a permanent venous catheter

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

On-line CME Webcast Discusses Skin Cancer

OSUWexnerbloglogo2014 On-line CME Webcast Discusses Skin Cancer. Skin cancer is the most common cancer in the United States. The good news is that we can usually prevent it. The bad news is that we usually don’t. On this CME webcast, we’re going to take a look at non-melanoma skin cancers with the two most common being basal cell carcinoma and squamous cell carcinoma. Joining our moderator in the studio is Mohs surgeon and Assistant Professor of Internal Medicine from the Division of Dermatology, Dr. David Carr.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DESCRIBE the incidence, risk factors, clinical presentation, and treatment of Basal Cell Carcinoma (BCC); and DESCRIBE the incidence, risk factors, clinical presentation, and treatment of Squamous Cell Carcinoma (SCC).

You’ll also learn about the following:

  • The Ugly potential of non-melanoma skin cancers
  • Common anatomic locations
  • Sunscreen
  • Who to regularly screen for skin cancers and how to screen them
  • When to biopsy a suspected skin cancer
  • Treatment options for actinic keratosis
  • Mohs surgery

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.